Survey and Research Archives | Page 24 of 142 | Be Korea-savvy

Archive by category Survey and Research

Fermilab: Muon g-2 announces most precise measurement of the magnetic anomaly of the muon

Fermilab: Muon g-2 announces most precise measurement of the magnetic anomaly of the muon

The third and final result, based on the last three years of data, is in perfect agreement with the experiment’s previous results, further solidifying the experimental world average. This long-awaited value will be the world’s most precise measurement of the muon magnetic anomaly for many years to come. Batavia, Ill., June 04, 2025 (Korea Bizwire) [...]

Hong Kong and New Zealand, the easiest jurisdictions for doing business in APAC, says GBCI 2025

Hong Kong and New Zealand, the easiest jurisdictions for doing business in APAC, says GBCI 2025

LONDON, June 04, 2025 (Korea Bizwire) – The Global Business Complexity Index (GBCI), recently launched by TMF Group, analyses the business environment of 79 jurisdictions, accounting for 94% of the world’s GDP. It also ranks them based on over 250 indicators of business complexity, with the jurisdiction ranked 1st as the most complex and the jurisdiction ranked 79th, [...]

GBI Launches Green Globes® Data Center Campus Certification Alongside Compass Datacenters for Sustainable Digital Infrastructure

GBI Launches Green Globes® Data Center Campus Certification Alongside Compass Datacenters for Sustainable Digital Infrastructure

PORTLAND, Ore., June 02, 2025 (Korea Bizwire) – Green Building Initiative (GBI) announces the release of the Green Globes Data Center Campus Certification, tailored to the unique operational and infrastructure demands of data center campuses. The innovative offering provides data center owners and operators with a streamlined, efficient, and cost-effective way to assess and certify [...]

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research [...]

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-’749 (olanzapine) to Date

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-’749 (olanzapine) to Date

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-’749 after more than 3,400 subcutaneous injections in study participants to date As a leader in neuroscience, Teva [...]

The UK, the Netherlands, Egypt and Saudi Arabia among likely winners in the changing world order

The UK, the Netherlands, Egypt and Saudi Arabia among likely winners in the changing world order

TMF Group today launched its 12th annual study on global business complexity, ranking countries according to the burden of their rules for doing business. LONDON, May 28, 2025 (Korea Bizwire) — The Global Business Complexity Index (GBCI) studies over 250 indicators of complexity in 79 jurisdictions that represent 94% of the world’s GDP. The complexity that the [...]

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease Candidate demonstrates Teva’s commitment to bringing important new treatment options to underserved patient populations TEL AVIV, Israel, May 27, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries, Ltd. [...]

Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense

Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA). The RENASYS TOUCH NPWT System demonstrated clinical efficacy,1,2,3,4 and operational fitness [...]

For the First Time in Dubai Two Restaurants are Awarded Three MICHELIN Stars

For the First Time in Dubai Two Restaurants are Awarded Three MICHELIN Stars

Trèsind Studio becomes the first Indian restaurant in the world to receive Three MICHELIN Stars FZN by Björn Frantzén enters the Guide with Three MICHELIN Stars in its first year The MICHELIN Guide Dubai 2025 selection also includes 2 new One MICHELIN Stars and 5 new Bib Gourmand restaurants DUBAI, United Arab Emirates, May 23, [...]

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).  Next generation SIRPα inhibitor BI 770371 was shown to be well tolerated alone and in combination with PD1 [...]